Call Us: 1300 775 597

Neovia develops oncology drugs that may enhance immunotherapy response to overcome drug resistance and has begun a Phase 1 clinical trial designed to evaluate our lead multi-inhibitor, (NEV-801), that has the potential to treat patients with advanced drug-resistant cancers as monotherapy, or in combination with immunotherapy.

  • Date:¬†January,¬†2017
  • Technologies: PSD, HTML5/CSS, JS, PHP
Visit Website